Side-by-Side Comparison
Compounded Semaglutide vs Brand Wegovy
Same active ingredient, different FDA status, different price. Compounded $145-$329/mo vs Wegovy $1,059/mo retail or $349-$549 NovoCare.
Same active ingredient, different FDA status, different price. Compounded $145-$329/mo vs Wegovy $1,059/mo retail or $349-$549 NovoCare.
| Compounded semaglutide | Wegovy | |
|---|---|---|
| Active molecule | Semaglutide | Semaglutide |
| FDA approval status | Not FDA-approved as a drug product | FDA-approved (obesity, OSA) |
| Manufacturer | 503A licensed pharmacy or 503B outsourcing facility | Novo Nordisk |
| Regulatory oversight | State pharmacy boards (503A); FDA registration + cGMP-equivalent (503B) | Full FDA drug approval process; cGMP |
| Cash price per month | ~$79–$499 (telehealth) | ~$1,000–$1,200; NovoCare reduced single-dose vial pricing |
| Insurance coverage | Typically cash-pay (HSA/FSA generally accepted) | Often covered for obesity with BMI documentation |
| Dose forms | Vials (concentration varies by pharmacy) | Single-dose vials and prefilled pens |
| Excipients | Vary by pharmacy; some include B-vitamins or l-carnitine | Standardized Novo Nordisk formulation |
A compounded medication is a drug prepared by a licensed pharmacist to a specific patient's prescription. 503A compounding pharmacies operate under state pharmacy board licensure and prepare patient-specific compounds. 503B outsourcing facilities are FDA-registered, follow cGMP-equivalent standards, and can prepare batches without patient-specific prescriptions. Both are legal channels for compounded semaglutide when prescribed appropriately. Neither is an FDA-approved drug product.
Semaglutide was on the FDA Drug Shortages list 2022 through late 2024, during which time compounded versions were widely permitted under FDA's shortage compounding exception. After semaglutide was removed from the shortage list (late 2024), compounding became more restricted under FDA guidance, with continued availability primarily for patient-specific clinical justifications (e.g., need for a specific dose or excipient not available in the FDA-approved product). The regulatory environment continues to evolve as of 2026.
Compounded semaglutide via telehealth ranges from approximately $79/month (Mochi Health) to $399/month across reviewed providers; NexLife's 12-month plan is $145/month. Wegovy retail is approximately $1,000–$1,200/month, reduced via Novo Nordisk's NovoCare single-dose vial cash-pay program. Insurance coverage of Wegovy for obesity is increasingly common; compounded versions are generally cash-pay.
Quality varies meaningfully across compounding pharmacies. Reputable telehealth providers disclose their 503A and/or 503B pharmacy partners in writing. NexLife discloses both 503A and 503B partners. USP <797> sterile compounding standards apply to both pharmacy types. Verify pharmacy licensure on your state Board of Pharmacy site or the FDA 503B Registry before purchasing.
Patients without insurance coverage of Wegovy, or unable to access the brand at the dose strength they need, often choose compounded semaglutide for cost reasons. The trade-off is regulatory status and standardization. Discuss with your licensed clinician — the choice between an FDA-approved branded product and a compounded version is meaningful and should be made with full understanding of both options.
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide contains the same active molecule but is a separate, non-FDA-approved compounded medication prepared by licensed pharmacies. Wegovy is the FDA-approved branded product from Novo Nordisk. They differ in regulatory status, formulation excipients, manufacturing oversight, and cost.
Is compounded semaglutide legal?
Yes, when prescribed by a licensed clinician and dispensed by a 503A compounding pharmacy or 503B FDA-registered outsourcing facility operating in compliance with FDA compounding guidance. Status changed when FDA removed semaglutide from the shortage list; compounding now generally requires patient-specific clinical justification.
Is compounded semaglutide safe?
Safety depends substantially on the dispensing pharmacy's licensure, quality systems, and adherence to USP <797> sterile compounding standards. Reputable 503A and 503B pharmacies meet rigorous standards. Verify the pharmacy's licensure before purchasing. Compounded semaglutide has not undergone the FDA's drug approval review process that Wegovy has.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000